Thanks for providing your contribution.

Yeah but this is a direct offering. Not public. Maybe set up to short for the tuts to cover but it dropped considerably lower than what they are bought it for.

Hopefully the dropped it to pick up cheap shares before the german surpreme court decision

According to this study using Bevacizumab the p2 results don’t seem very impressive. There drug is a combo with Bevacizumab correct?

https://ar.iiarjournals.org/content/38/10/5877

For a company so cash strapped being the highest level sponsor is interesting.

Thanks, sorry for the confusion

Why is Monday the deadline. Flipper said last data collection was 8/19/20. Just trying to understand why 8/16/21 is the deadline.

You seem to not understand his point. He believes that if the price crashed to .10 it would be so mispriced that he would buy 400m shares. Lol. He doesn’t see the stock crashing that low so he isn’t selling.

Of course I’m speaking for thermo. He can correct me if I’m wrong in my view.

Monster potential here. Will really breakout if revenues shows what is capable of their SaaS model

Thank you sharing your analysis and personal story. Always much appreciated.

I’m a big fan of many of you on the board sharing your opinions, analysis, facts, and presenting your case on the drug.

Hopefully patients and investors win.

Why do they need a contract with Uber. They can go straight to any rideshare driver. It’s their car. I think that’s whats happening. No need to share revenue with Uber. These rideshare drivers work with all the apps. Uber, lyft, door dash. Alfi though may be exclusive.

Can anyone comment on when full data release will be. I read mid year but also heard ceo say on a call end of year.

Thanks

Thanks for the reply. I bought in the 1.80 range. Thanks for the tip. Hoping it works out for all of us.

Okay thank you, I think what threw me off is that 131 should be MGMT. it appears you have 162 as MGMT. I may be reading it wrong.

Thanks for putting this together. It’s interesting.

The MGMT gene promoter was methylated in 39.6% of patients (n?=?131) and unmethylated in 48.9% (n?=?162), with information not available for 11.5% (n?=?38)

This was manipulated down based on great data. Just look at PFS of 9 months on ITT vs 3 months on BAC. There will be clear separation of OS and quality of life appears to be really good. This trial is still powered 1:3 between BAC and ITT. Also the complete data will allow for reimbursements in EU and UK. I see interest coming into this stock and the volume looks good. New money coming in due to warrant conversion. Good luck

Hi Neal, have you heard from Rosalind. The data read seemed good to me. Unsure of the market reaction. The safety is in line and appears no unmanageable treatment related reactions.

Anyone have any updates on when results will be posted. Nearing the end of the quarter now.

Thanks for providing your perspective to the open forum. I’m a fan.

Bought today. News seems great. Need US Rare Earth independence

Bought on the pull back today.

Lots of things to like

Low float
Platform technology
Rare indication
Derisked p3 based on published studies
1000+ procedures performed
Real benefit to patients fighting cancer
New management team trying to build trust. CEO interview seemed to indicate knowledge and honesty

If you form a SPAC. Please let me know, so I can buy some shares.

Same here. Thank you for your time. Let’s go DCTH.

Thank you, that helps. Would have been nice if they stayed within the max limit.

Huge fan of the board and all its members. Have learned a lot.

Can anyone confirm if the total OS is 1.5b. I know the max authorization is 1.2b. I’ve had a tougher time with my limited knowledge making sense of some of the filings related to total OS.

TIA

Does that mean your entire position? Or just some of it?

Hi Neil, are you taking phone calls to discuss the company? I’d like to get some of your insight.

Thank you

After listening to the Florida doctor this tech seems very important step to fight met liver cancer. Even if it shrink the tumor enough for further resection and IO therapy to turn the tide.

Seems like this should be priority review and approval by FDA

I’m not sure why this isn’t a buzz.

What are your thoughts Neil?

Thanks

Thanks

Who all is holding here? Price seems to be flat. What are the expectations?

Sorry, meant top line data. Has the company given you any indication? Where are you pricing the market cap on good data? 1b?

Thanks

Neal, it appears you are a well connected and big time investor. When do you think TLD will be posted? Thanx

Thanks for your post. It’s great following someone like you on these boards.